Showing results (151-160 of 164) with videos related to

Sort By:
Pageof 17
Hinyokika Kiyo. Acta Urologica Japonica|January 15, 2014
[The diagnostic value of pre-biopsy magnetic resonance imaging for precise detection of clinically localized prostate cancer compared to post-biopsy setting]Masahiro Takahashi, Akio Horiguchi, Shinsuke Tasaki, et al.
The Prostate|October 24, 2015
A pilot study of photoacoustic imaging system for improved real-time visualization of neurovascular bundle during radical prostatectomyAkio Horiguchi, Kazuhiro Tsujita, Kaku Irisawa, et al.
Hinyokika Kiyo. Acta Urologica Japonica|July 12, 2011
[Clinical experience of 52 patients undergoing laparoscopic radical prostatectomy]Keiichi Ito, Hidehiko Yoshii, Akira Miyajima, et al.
Oncology Letters|July 12, 2017
Clinical outcomes of percutaneous radiofrequency ablation for small renal cancerKeiichi Ito, Shigeyoshi Soga, Kenji Seguchi, et al.
Hinyokika Kiyo. Acta Urologica Japonica|May 3, 2013
[Evaluation of clinical results in patients undergoing laparoscopic nephroureterectomy]Shinsuke Hamada, Keiichi Ito, Masahiro Takahashi, et al.
Japanese Journal of Clinical Oncology|May 8, 2019
Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapyGo Kaneko, Suguru Shirotake, Koshiro Nishimoto, et al.
Japanese Journal of Clinical Oncology|November 9, 2018
Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinomaKeiichi Ito, Ayako Masunaga, Nobuyuki Tanaka, et al.
European Urology Focus|July 21, 2017
External Validation of the MSKCC and IMDC Risk Models in Patients Treated with Targeted Therapy as a First-line and Subsequent Second-line Treatment: A Japanese Multi-institutional StudyNobuyuki Tanaka, Ryuichi Mizuno, Keiichi Ito, et al.
Urologic Oncology|November 10, 2016
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk modelNobuyuki Tanaka, Ryuichi Mizuno, Yota Yasumizu, et al.
Clinical Genitourinary Cancer|April 23, 2016
Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell CarcinomaSuguru Shirotake, Yota Yasumizu, Keiichi Ito, et al.
Pageof 17